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Objective: This study assessed the macro level effects of multiple and varied forms 
of clinical guidance for medication based treatment for heart failure. Drug mention 
rates for physician visits by patients with heart failure were evaluated with respect 
to the dates of publication of large randomized trial evidence and guidelines. 
Design: Retrospective, cross-sectional series study 
Methods: We used the National Ambulatory Medical Care Survey (NAMCS) for 
years 1993-2000, which captures a probability sample of visits to United States 
physicians to provide national estimates. We examined heart failure coded visit 
drug mentions alongside research published during the same period to examine 
trends in medication prescribing and the aggregate influence of the dissemination 
of research findings. Multi year estimation equations from the National Center for 
Health Statistics (NCHS) were used for calculation of sampling error. 
Measurements: Medication mention rates were calculated for four sequential two-
year periods. Relative standard errors (RSEs) were generated for measuring 
reliability and stability of our findings of changes in medication mention rates for 
beta blockers, angiotensin converting enzyme inhibitors, spironolactone, and 
angiotensin receptor blockers. Stratification and logistic regression models were 
used to provide insight into other possible predictors. 
Results: The number of visits by a patient with heart failure to physicians was not 
statistically significantly different across the eight years of interest. The estimated 
medication mention rate of beta blockers, spironolactone, and angiotensin receptor 
blockers increased dramatically, but the number and rate of mentions was too low 
11 
( for statistical reliability. There was an adequate number of drug mentions of 
angiotensin converting enzyme inhibitors for reliable aggregate estimates, but there 
were not adequate numbers of mentions to demonstrate statistically significant 
increases over the eight years. Logistic regression models showed strong 
associations between increased drug mentions and later two year periods. This 
association was demonstrated by progressively larger odds ratios (ORs) for 
subsequent periods when the first two year period is used as a referent baseline. 
Discussion: The increases in medication mention rates for all medications 
corresponded with the findings of the major trials and evidence which we assessed. 
The NAM CS sample size and the low percent of drug mentions in the given 
therapeutic categories resulted in a lack of statistical power for determining 
statistical significance of the changes in medication mention rate. 
Conclusion: We conclude from our collected information, and statistical analyses 
that the NAM CS demonstrated marked trends, but this study was inadequately 
powered to establish statistical significance. 
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MEDICATION PRESCRIBING IN HEART FAILURE: TRENDS IN DRUG 
TREATMENT AND EVIDENCE FROM THE PAST TEN YEARS 
INTRODUCTION 
The Institute of Medicine's 2001 report, Crossing the Quality Chasm, 
focused attention on the high level of unexplained variation in medical practice 
quality. Geographic variance, inter-provider inconsistencies, and gaps in quality 
highlighted the need for rational treatment. This effort for rational treatment has 
resulted in a major movement in the medical community to align the practice of 
medicine to methodically developed best practices. This broad movement is called 
'Evidence Based Medicine.' 
Evidence Based Medicine relies on appropriate and well-conducted 
studies[ 1]. After research results are generated, this information must be 
effectively disseminated to practitioners[l]. Lastly, this information must be 
appropriately incorporated into the medical practitioner's daily work[2]. The 
current healthcare system suffers from flaws at each of these stages. There are 
unanswered questions due to a lack of high quality studies. Distribution of 
knowledge is also difficult[3]. The current rate of nearly 10,000 trials annually[ 4] 
creates an enormous burden on our current information dissemination system. 
Congestive Heart Failure (CHF) provides a useful subject for the 
investigation of the impact of evidence-based medicine for two primary reasons. 
The prevalence, incidence, and burden of CHF have a substantial impact on the 
U.S. health and healthcare. CHF affects 2-4.8 million people in the United 
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( States[5, 6]. It has an incidence of 400,000-700,000 new cases each year, and is 
the leading cause of hospitalization[6]. O ' Connell and Bristow estimated the 
U .S. 's total direct healthcare costs in 1991 for heart failure treatment to be $38.1 
billion or 5.4% of 1991 ' s total U.S. healthcare expenditure[?] . These substantial 
direct healthcare costs fail to capture the substantial societal costs that are attributed 
to heart failure's mortality and disability. This large medical burden also creates an 
availability of data due to the number of medical encounters recorded. 
The second reason for the selection of CHF for evaluation of the impact of 
evidence on practice is the numerous changes in recommendations for drug 
treatment in recent years. Changes in our understanding of CHF have occurred 
frequently since the 1940's, and the subsequent evolution ofrecommended 
pharmacological interventions in the past decade are of particular interest. This 
could not be more clearly illustrated than the case of beta-blockers that, years ago, 
would be contraindicated treatment, and now are considered a cornerstone of 
therapy for this condition [8, 9] . 
This research is closely related to a broad group of guideline and research 
implementation studies. In 2000, Jones et al. expressed the need for "complex 
interventions (to be) assessed en bloc rather than trying to disentangle the effects of 
individual components of guidance ... "[ 1 O] It is in the spirit of this astute 
observation in which this research is based. By placing emphasis on the search for 
the aggregate changes in medication prescribing, alongside an extensive summary 
of the published evidence during the period, a more complete picture can be 
captured. 
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( While several guideline implementation focused studies address the 
prescribing rates of Angiotensin Converting Enzyme Inhibitors (ACEis) [11-16] in 
heart failure, there is a lack of studies addressing the other medications with 
favorable supporting mortality studies. Recent studies and guidelines clearly make 
the case for the utilization of beta blockers, spironolactone, and Angiotensin 
Receptor Blockers (ARBs) depending on the type of heart failure. The association 
between these published findings and guidelines and medication prescribing is the 
primary focus of this investigation. This study examined national trends in 
medication prescribing rates of beta blockers, ACEis, spironolactone, and ARBs. 
These changes were exhibited alongside the studies and guidelines which were 
expected to influence prescribing. This study also identified and tested possible 
demographic and medical predictors of drug mentions in the ambulatory setting for 
relevance to prescribing of these medications. 
Our hypothesis was that we would see increases in drug mentions in the 
immediate and subsequent two year periods of published large trial evidence which 
demonstrated mortality or hospitalization benefits. We also hypothesized that 
guidelines would have a similar impact by magnifying previous findings. 
3 
METHODS 
This study is a retrospective analysis of a series of cross sectional studies 
assessed in parallel with a comprehensive review of the most influential published 
research. 
Data source 
We utilized the National Ambulatory Medical Care Survey (NAMCS), 
using years 1993-2000 to examine changes in prescribing patterns. The NAMCS is 
a publicly available national probability sample survey frequently used by various 
leading epidemiological researchers. The study, which captures information on 
visits to office-based physicians, has been performed annually since 1989 (and 
sporadically prior). The survey instrument is reviewed and slightly altered every 
other year, causing minor changes in content and coding. The NAMCS is well 
described as a series of cross-sectional studies with visits to physicians as the unit 
of measure in the survey. The complex sample design is segmented into three 
stages. The first stage selects primary sampling units (PSUs), which consist of 
counties, groups of counties or equivalent areas. The second stage involves 
selection of physicians within the selected PSUs. Participating physicians are 
randomly selected from master lists maintained by the American Medical 
Association (AMA) and the American Osteopathic Association (AOA). From the 
selected physicians, the group of participants is limited to non-federally employed 
practitioners, and excludes the specialties of anesthesiology, radiology, and 
pathology. This selection comprises the in-scope number of physicians by year 
presented in table 1-1. 
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In the third stage, in-scope physicians are randomly assigned to varying 
one-week reporting intervals. Trained personnel provide physicians or their 
designee instructions on proper survey procedures and are provided the appropriate 
materials prior to the initiation of data collection. During this selected week, the 
practitioners complete a survey form for a random sample of approximately 30 
visits. Visits to nurse practitioners, physician's assistants and other non-physician 
prescribers are not captured by this survey. 
The number of in-scope selected physicians and the yearly response rates 
are presented in Table 1-1. Further details on the NAMCS sample design are 
available from published reports[l 7] or from the National Center for Health 
Statistics' (NCHS) website. To produce more stable and reliable estimates, two 
years of data were combined to produce each of our four periods of interest. 
Sample 
NAMCS databases for the corresponding years were limited to patients with 
an International Classification of Diseases revision 9 (ICD-9) code indicating CHF. 
The relevant ICD-9 codes used to identify CHF visits, as well as pertinent 
comorbidities are located on table 1-2. Under this disease-based sub-sample, 
additional data on diagnosis, treatment, and demographics were utilized for 
analysis. 
Outcome 
The NAMCS attempts to capture all current medication therapy occurring 
during the visit. Instruction on survey completion directs that all new or continued 
medications should be recorded on the survey form. The survey allowed for the 
5 
( documentation of five (1993-94) or six (1995-2000) medications, which are 
referred to as drug mentions. The drug mention rate for CHF related medications 
was our surrogate outcome measure for the prescribing rate. Evaluation of the 
appropriateness of drug mentions was not be made in this study. The visit data 
found in the NAM CS can not be used to extrapolate the rate of drug usage by 
patient. 
Analysis 
Articles reviewing medication treatments for CHF were utilized to identify 
relevant therapeutic medication categories. Specific drug entities were identified 
using a comprehensive list of medications prescribed to CHF patients during the 
selected years. Medications that matched the previously identified therapeutic 
categories were recorded without regard to Food and Drug Administration (FDA) 
indications of individual agents. All medications recorded in the NAM CS survey 
were manually reviewed for inclusion as a second check to ensure that all 
medications used for CHF were identified. This list of relevant medications 
appears in table 1-3. This medication list was converted to the coding system 
developed by the NCHS, which is used by the NAM CS. Details on the collection 
and coding of this drug information by the NCHS are available.[18] Combination 
products, those with multiple active ingredients in one dosage form, were omitted 
after a preliminary analysis demonstrated that all such products accounted for very 
few drug mentions, and a small percent of all CHF drug mentions. Early analyses 
demonstrated that a majority of these medications were combinations of two 
diuretics, a common type of medication for symptomatic relief in CHF. 
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This study adopted the standards of the NCHS, which does not publish 
statistics on samples that are of insufficient size to rely on the central limit theorem, 
which states that samples of sufficient size (30 or more), approximate the value 
which would be found in the entire population. The NCHS utilizes relative 
standard errors (RSEs) to measure the reliability and precision of their sample's 
weighted national estimates. The RSE captures the degree sampling variability and 
nonsystematic biases present in the sample. NAMCS reports approximate the RSE 
through the use of first order Taylor approximations using SUDAAN (previously 
an abbreviation for Survey Data Analysis, which is no longer used as a title) 
statistical software. Further information on SUDAAN statistical software, which is 
specialized in the analysis of clustered data, is available[l9]. Less precise methods 
for approximations ofRSE for single years are published with the NAMCS 
advance data reports. Equations for approximation across multiple years were 
obtained directly from NCHS, and are located in Appendix A and B. These 
methods use the least reliable year being aggregated to calculate RSEs for the 
larger group of samples. 
Predictor selection 
_Preliminary predictors of drug mentions were selected from among the 
demographic variables collected by the NAMCS. The patient's recorded sex, age, 
race, payment type, and comorbidities expected to influence the prescribing of the 
therapeutic drug categories were chosen for analysis. Age was recoded to those 
less than sixty, sixty to sixty-nine, seventy to seventy-nine, and eighty and older. 
Race was recoded to a dichotomous white and nonwhite variable due to insufficient 
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( visits for further breakdown. Visit payment coding by the NAM CS in periods 1 
and 2 allowed for multiple visit payments to be captured. Beginning in period 3, 
the survey form requested a single entry of only the primary expected payment. 
Due to this change, this information could not be recoded without substantial 
ambiguity in interpretation of this variable, therefore this information appears only 
on table 1-4 and was not included in further analysis. Health Maintenance 
Organization (HMO) status in periods 1 and 2 did not allow for the coding of blank 
or unknown HMO status. HMO status underwent no transformation, and therefore 
all blank and unknown entries in this variable appear in periods 3 and 4. Due to 
this variable change, HMO status was omitted from the logistic regression analysis. 
The presence of diabetes, asthma, or hypertension would be expected to 
influence the rate of prescribing of medication in several of the therapeutic classes. 
Beta blockers would be expected to be prescribed less :frequently in diabetics and 
asthmatics, and more :frequent in hypertensive patients. ACE inhibitors would be 
expected to be prescribed at higher rates in diabetics. For this reason, visits 
involving these conditions as well as heart failure were also identified. Due to the 
limited number of asthmatics captured by the sample, these visits were not 
analyzed further. 
Descriptive analyses were performed using Statistical Package for the 
Social Science (SPSS version 10.0 for Windows). Each visit record was flagged 
for drug mentions of relevant medications that affect heart failure mortality or 
hospitalization. These records were weighted to produce national estimates, using 
visit weighting by the NCHS in the NAM CS data files. These weightings take into 
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( account the complex multi stage probability procedure and adjust for nonresponse. 
A weighting adjustment is also made for the physician to population ratio. 
Beginning in 1995, a weight smoothing technique was utilized in these weightings 
as well.[20] These visit based rates were considered in parallel with the published 
studies, as well as their statistical stability and reliability. 
A list of published studies of medication usage with hospitalization or 
mortality outcome measures and treatment guidelines in heart failure was 
generated. The focus was on the larger studies which individually influenced the 
current standards and guidelines. This clinical trial list, organized by publication 
dates and medication therapeutic category, was utilized to watch for changes in 
practice patterns. This list descriptively outlined the outcome measure used, and 
the direction of the findings . Review articles, although likely influential in the 
aggregate, were not included due to the difficulty in determining completeness and 
interpretability. Guidelines that were not generally published or disseminated 
extensively, such as those by the American Medical Directors Association, were 
also excluded. These lists, by therapeutic classification, populate tables 2-1, 3-1, 4-
1, and 5-1. 
In measuring the degree of statistical significance and precision in our 
estimates, RSEs were chosen in preference to confidence intervals (CD or statistical 
tests since RSEs are the standard method utilized within the NCHS for the 
NAMCS, providing for a "gold standard" for this type ofresearch. Calculations of 
RSE were made according to previously unpublished multi-year estimate 
equations, which are available from the NCHS, or in the appendix of this thesis. 
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The complex sampling methods utilized in the NAMCS requires the calculation of 
cell sizes and RSEs to ensure a stable and precise estimate. The RSE can be 
translated to a confidence interval by multiplying the RSE by the estimate to obtain 
the standard error. There is a 95% confidence that the true value lies within twice 
the standard error of the value produced by the NAMCS, with the caveat that RSEs 
greater than 30% are considered unreliable by the NCHS definition. 
Two different methods were utilized to assess and control for other possible 
influences on the drug mention rate. The first method consisted of stratification of 
the cases into subgroups and outcomes. This simple method was valuable for 
accessing the importance of individual predictors in isolation. The stratified 
analysis assessed the percentage of drug mentions by age, sex, race, diabetic status, 
and hypertensive status. The stratified analysis also listed the percent of drug 
mentions by those which were and were not related to an HMO. The stratified 
percentages on HMO status excluded those reporting blank or unknown in periods 
3 and 4. These were excluded from the table to minimize potential confusion, and 
because a blank or unknown coding does not have a conceptual association with 
outcomes of interest. 
The second method to control for other predictors was a multivariate 
standard logistic regression model to appraise the differing impact of the many 
suspected predictors simultaneously. In this multivariate analysis, period was our 
proxy measure for the impact of the evidence when in agreement with the timing 
and direction of the various findings. Odds ratios (OR) were used to assess each 
predictor's impact on prescribing where the odds of the referent category is set to 1. 
10 
r 
An OR> 1 indicates an increased association between the outcome of drug mention 
and the listed characteristic, while an OR<l indicates a decreased association. Our 
confidence intervals represent the range that we are 95% statistically confident that 
our true values would fall within. 
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RESULTS 
Limiting the records to those with a diagnosis of heart failure by the ICD-9 
code listed on table 1-2 returned 1725 unweighted records for the four periods of 
analysis. After weighting, these surveys approximated 47 million visits over eight 
years. The number of visits over the four two-year periods remained relatively 
stable as shown on table 1-5, ranging from a high of 12.3 million in period 1 to a 
low of 11.2 million visits in period 3. The confidence intervals for all four periods 
overlap, demonstrating a lack of statistically significant difference. 
Demographics of the visits are detailed on table 1-4. The sex of patients 
visiting for CHF was approximately evenly split with female visits in a slight 
majority (51.9%). Older individuals accounted for more visits than younger 
patients, with age 80 or older individuals accounting for the largest number of 
visits. Whites accounted for a majority of the visits (87.3%) as compared to non-
whites. Diabetic patients comprised 14% of the sample, while asthmatics 
comprised only 1.3% of the estimated national visits for CHF. Hypertension was 
coded for the visits 18% of the time, but may have been omitted from coding more 
frequently if those recording information considered it less relevant in the light of a 
CHF coding. Recoded payment indicates a large number of Medicaid visits 
(55.3%) and blank or unknown status (22.8%), which likely resulted from the 
recoding of multi-coded payments from earlier periods to a status of "unknown". 
Beta blockers 
Beta blocker drug mentions were found to increase steadily and 
incrementally through the four periods, from 0.4 million mentions in period 1, to 
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( 1.6 million mentions in period 4. These estimates must be interpreted cautiously as 
the RSEs for all four periods exceed the 30% cutoff for stable and precise estimates 
as defined by the NCHS. 
Large mortality and hospitalization studies during the four periods for beta 
blocker usage in heart failure were numerous, as were guidelines, as listed on table 
2-1. In period 1, the Cardiac Insufficiency Bisoprolol Study (CIBIS) study was 
published, which was the first large trial to evaluate the impact of beta blockers on 
CHF mortality and hospitalization. Period 2 brought a set of trials in the US 
Carvedilol Heart Failure Trials Program, which consisted of five total publications. 
Three of the studies in the program, which measured mortality, as well as the 
published report that summarized them, appear on the table. The last of these 
reports extends into period 3. The first publication of the now widely known 
American College of Cardiology (ACC)/ American Heart Association (AHA) 
guidelines for CHF occurred during this second period of time. The third period 
included the last part of the US Carvediolol Heart Failure Trials Program, and one 
set of published guidelines. The last period brought another two large trials, one 
positive and one negative for beta blockers. Period 4 also produced another 
guideline, the first from the Heart Failure Society of America (HFSA), as well as 
an observational review of the Studies of Left Ventricular Dysfunction Treatment 
(SOL VD) trial, which was originally designed to determine the efficacy of ACE 
inhibitors. 
Stratification of beta blocker drug mentions by various subgroups are 
outlined on table 2-2. Beta blocker mentions in visits by males with CHF occurred 
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( at nearly twice the rate in women each two year period. The low number of 
nonwhite visits during the four periods produced sporadic mention rates. Diabetes 
is negatively associated with a beta blocker mention, while hypertension appears to 
have a positive association, as would be predicted. Those known to be in an HMO 
had nearly twice the rate of drug mentions as those known to not be in an HMO. 
Lastly, utilizing logistic regression, we considered the relative importance 
of our predictors on beta blocker drug mentions. The OR and 95% CI for our 
predictors are found on table 2-3 . In our model for beta blockers, hypertensive 
patients (OR 1.177, CI 1.173-1.180), and males (OR 1.945, CI 1.940-1.949) were 
positively associated with a drug mention for beta blockers. Diabetic patients (OR 
.585, CI .583-.587) and nonwhite patients (OR .690, CI .687-.692) were negatively 
associated with a beta blocker drug mention. The period of the visit showed the 
strongest association, with visits in period 4 (OR 3.754, CI 3.741-3.766) showing a 
dramatic difference from the referent period 1. Periods 2 (OR 1.171 , CI 1.166-
1.176) and 3 (OR 2.333, CI 2.325-2.341) were between the other two periods. 
Angiotensin converting enzyme inhibitors (ACEis) 
ACE inhibitor drug mentions have been a recognized part of heart failure 
therapy for more than a decade. Their utilization rate shows that they had a 
moderate level of usage during the first period (3.4 million drug mentions) as 
shown on table 1-6. This rate increased substantially by the fourth period ( 4.3 
million mentions). Drug mention rates in ACEis were large enough to allow for 
much more stable RSEs, making for stable estimates in three of the four periods. 
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ACE inhibitors present a different case than the other three classes of 
medications in that the mortality studies were performed earlier. The first study to 
show clinical benefit was published in 1983 [6, 21], and mortality studies followed 
shortly[22]. The major studies of the efficacy of ACEis in decreasing mortality 
and hospitalizations were completed before our first period of analysis as shown on 
table 3-1. The first such study was published in 1987, with a string of later studies 
in the early 1990's just prior to our period 1. Due to this earlier clinical study 
timing versus our other therapeutic categories, ACEI provide an opportunity to 
observe the impact of guidelines without simultaneous changes in research 
findings. 
Stratification by subgroups does not show the same dramatic subgroup 
differences found in beta blockers. Table 3-2 documents that this sample had very 
similar drug mention rates by sex, race, hypertension, or HMO coverage. One 
exception was found among diabetics. In the last two periods the diabetic mention 
rates are nearly double the non-diabetic rates. 
The logistic regression model for predictors of ACEI drug mentions is 
presented on table 3-3. ACEI prescribing varied between periods yet no strong 
predictors were found. In all but the first age category, the ORs were consistently 
similar. For sex, race, and hypertensive status, the ORs were very close to one. 
Only diabetics had a remarkable association (OR 1.558, CI 1.555-1.561). 
Spironolactone 
Spironolactone prescribing was difficult to assess due to extremely low 
drug mention rates for this drug, which were not statistically stable or reliable. As 
15 
would be expected from table 1-6, few mentions occurred in periods 1-3. There is 
a jump in reports in period 4 (to 0.4 million mentions) . 
There were no large mortality based clinical trials with evidence for 
spironolactone use in heart failure until the Randomized Aldactone Evaluation 
Study (RALES) [23] which occurred in period 4 as shown on table 4-1. The 
resulting weighted visits are stratified on table 4-2, but these numbers represent 
very few surveys in all periods, and should be considered with caution. The 
logistic regression analysis reveals the dramatic increase in association in period 4 
(OR 3.542, CI 3.519-3.564) as compared to period 1. The three older age groups of 
the four are negatively associated with spironolactone use (ORs from .510 to.589) 
as compared to those younger than 60 year old, which is outlined on table 4-3. 
Angiotensin receptor blockers (ARBs) 
Drug mentions of ARBs increased from period 1 (173020 weighted drug 
mentions), to period 4 (530420 weighted drug mentions) as seen on table 1-6. The 
largest change occurred between periods 2 and 3 (360,878 increase in weighted 
estimate mentions). 
ARBs differ from the previous therapeutic categories in that the evidence 
for their use is not based upon direct superiority against placebo, but rather based 
upon their equivalence to ACEI. The two studies which measured mortality and 
hospitalization, are the ELITE (in period 3) and ELITE II (in period 4) trials as 
listed on table 5-1 . These studies did not show statistically significant 
improvements in CHF related mortality over ACE inhibitors, but ELITE did show a 
slight but significant decrease in all-cause mortality [24]. The first ARB to be 
16 
( approved by the FDA was Losartan on April 14th, 1995 which interestingly falls 
during period 2 despite already having been available for coding by the NAM CS 
during period 1 [25] . Two other ARBs were approved during the third period, 
Irbesartan on September 30th, 1997, and Candesartan on June 4th, 1998[25] . 
Valsartan was not approved until after the 4th period, but was listed by the NAMCS 
by period 4. 
Differences shown on the stratified sample on table 5-2 are again difficult to 
interpret due to the poor reliability and stability of the period estimates due to low 
sample size and a low drug mention rate for ARBs. The evaluation of individual 
predictors through the logistic regression model is on table 5-3. The dramatic 
association with period is shown in period 3 (OR 3.115, CI 3.097-3 .132) and period 
4 (OR 3.767, CI 3.788) as compared to period 1. 
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DISCUSSION 
The eight years of NAM CS data on CHF visits showed statistically 
insignificant increases in drug mentions for all four therapeutic categories of 
medications which provide benefits in survival or decreased hospitalizations. 
Descriptively the mention rates change with surprising similarity to expected 
trends, but the lack of reliability of the data precludes statistical inferences to 
evaluate the role of chance in our findings. Beta blockers are of particular interest 
as the evidence supporting the use of beta blockers mounted during our four study 
periods, corresponding with a large increase in drug mention rates observed in the 
NAMCS weighted estimates. 
For beta blockers, the rate of drug mentions in period 1 is representative of 
the drug mention rate when only small trial and supporting theory was available to 
influence prescribing. If evidence were the only predictor of beta blocker use, 
period 2 would represent the impact of the first large randomized trial which 
occurred near the end of period 1. The guidelines directly reflect the prior large 
trials, and therefore the 1995 ACC/ AHA guidelines released in period 2 discuss 
beta blockers cautiously. In the end of period 2 a confirmatory study was 
published, and the rate of drug mentions doubled from the initial rate in period 3. 
In period 3 and 4, more evidence is published and the drug mention rate increased 
further, but still only mentioned in less than 15% of visits with patients with CHF. 
There are several reasons why the drug mention rate may be lower than 
might be expected. Some comorbidities would make a prescriber hesitant to 
prescribe a beta blocker, such as asthma or diabetes due to a relative 
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( contraindication. Unlike an absolute contraindication which would always be 
inappropriate, a relative contraindication would discourage, but permit prescriber 
judgments to use the medication with the comorbidity. The NAMCS does limit the 
number ofrecorded medications to five in period 1, and six in periods 2-4. 
Considering a patient visiting with CHF alone, we would expect many patients to 
be treated with an ACEI, diuretic, digoxin, and a beta blocker or spironolactone. 
When one diagnosis is associated with four or more medication mentions, it is 
likely that a form with space for six drug mentions is not adequate to capture all 
medications for all visits. The NCHS plans to increase the number of drug 
mentions which can be listed on the survey in coming years[26]. Some 
medications are available as combination products, meaning that multiple active 
ingredients would be in one tablet. Although captured by the NAM CS, these drug 
mentions were not recoded in this study since early testing showed that 
combination products accounted for few drug mentions. In this population a 
majority of these combination products is for diuretics, which fall outside the scope 
of this investigation. 
The large RSEs for this study create difficulties when using the NAMCS for 
analysis of specific disease states. Even with the frequently used practice of 
combining years [20, 27-29], limiting the number of visits by diagnosis quickly 
erodes the necessary power when using the approximation equations. Power is also 
eroded by the size of the estimate since it is related to the RSE[30]. Analysis of 
visits without weighting has very limited utility in describing the prescribing rate in 
the United States because the NAMCS is not a random sample, and therefore a 
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( 
report of the raw survey reports of visits is not representative of actual practice. 
These concerns, taken together, demonstrate the necessity of asking large questions 
with this data, or by using SUDAAN to calculate the precise RSEs, which at times 
allows for the use of substantially fewer visits than the more conservative estimate 
equations. 
Increases in drug mentions predicted by period are likely influenced by 
several factors in addition to large trials and guidelines. Over the broader period of 
1985-1999, Burt was able to show an increase in drug mention rate of 59%. This 
rate was largely attributed to the increasing age of the population, new drugs, drug 
coverage, and direct to consumer advertising[29]. Increasing age, although 
associated with CHF, did not result in an increase in the number of visits, nor was 
increasing age associated with a drug mention except with ARBs. New drugs are 
also a minor issue in these therapeutic classes, other than the ARBs. Direct to 
consumer advertising is also rare in CHF. It is likely other factors are having a 
greater effect on CHF than those that are impacting broader prescribing trends. 
ACEI mention rates appeared to increase slowly and steadily, although rates 
are remarkably low considering the broad agreement to the necessity of their use in 
CHF. Several published reports have addressed the inadequate prescribing rate of 
these medications in CHF[12-16]. With the majority of the studies on mortality 
benefits being prior to our study period, we expect that the guidelines have the 
greatest impact during the four periods. We find that period is a significant 
predictor of ACEI mentions, as is diabetic status, which is not surprising 
considering the great benefit of ACEis in this population[31] . Since ACEis and 
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ARBs have similar mechanisms of action and may be viewed by practitioners as 
being interchangeable, it is also possible that their trends should be viewed 
together, although guidelines and practice do firmly distinguish between the two 
classes. 
Assessment of spironolactone mention rates provides an opportunity to 
determine the impact of one large randomized trial. While some prescribing of 
spironolactone may be attributed to its diuretic properties for symptomatic relief, 
we do find that the mention rate increased dramatically, but not statistically 
significantly, after publication of the RALES trial. The spironolactone analysis is 
statistically limited by its low drug mention rate, which did not allow for a reliable 
or precise estimate. 
The increase in ARB prescribing is most pronounced in period 3. During 
this period we do have the first trial showing equivalence of ARBs to ACEis. 
During the third period, irbesartan and candesartan were approved, joining losartan, 
which was the only approved ARB during the previous period. Unlike the other 
therapeutic categories, guidelines discourage the use of ARBs in preference to 
ACEis, except where latter is not tolerated due to side effects [6, 8, 9, 32, 33]. 
These agents are more recent developments, and although not generally marketed 
directly to consumers, they certainly do have substantial sales force support from 
their respective manufacturers. Since the ARBs did not yet have FDA approval for 
the treatment of CHF during this period, this marketing influence should be a minor 
concern since the FDA prohibits marketing unapproved indications. 
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( Although in this study we were able to report rates of drug mentions which 
corresponded with the guidance provided by the most important studies, review 
articles and other smaller influences can not be accounted for. The guideline 
update from the ACC/AHA for CHF in 2001 also falls outside the focus of this 
study. Further studies in the reasons behind the rates of adoption of lifesaving 
medication, and effective interventions to ensure appropriate use are needed. 
We conclude from our collected information, and statistical analyses that 
the NAM CS demonstrated marked trends, but this study was inadequately powered 
to establish statistical significance. The trends showed dramatic increases in drug 
mentions which corresponded temporally with major published evidence. Beta 
blocker trends suggested that two studies were necessary to increase prescribing, 
perhaps due to prior theory which suggested the class to be contraindicated. 
Spironolactone, which unlike beta blockers would not have contraindication 
concerns, increased dramatically after only one large study. This suggesting that 
some prescribers are reacting quickly to new high quality evidence, but further 
research utilizing other data sets may offer more reliable answers in time. 
Although power limitations inherent to the NAMCS limited statistical 
inferences, the strengths of the NAMCS should not be ignored. The NAMCS is 
limited by resources, versatility, and anonymity. Federal resources for the NAM CS 
are limited, and the survey instrument attempts to capture an enormous number of 
topics. Physician participation is voluntary, and therefore anonymity is necessary 
for high response rates, which limits the data that can be released. The strengths of 
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the NAM CS include persistence over multiple years, national coverage, and 
extensive details about visits. 
Future research should be directed to establishing the degree to which these 
trends are statistically significant, which would require either more precise methods 
(notably the use of SUDAAN), or a different data source. Other data sources may 
involve primary data collection, or the utilization of regional data. It is important 
that research also be directed toward establishing optimal prescribing rates, which 
match the evidence to allow for benchmarking by individual health organizations. 
This information is necessary to evaluate the adequacy of the current evidence 
dissemination system. 
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Table 1-1: NAM CS Survey Response Rates by Year 
Year Physicians in Percent Total Surveys 
Sc~e Re.E_orti~ Returned 
1993 2464 73.0% 35,978 
1994 2426 70.2% 33,598 
1995 2587 72.8% 36,875 
1996 2142 70.0% 29,805 
1997 1801 69.2% 24,715 
1998 1806 67.9% 23,339 
1999 1728 62.9% 20,760 
2000 2049 67.7% 27,369 
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/ Table 1-2: ICD-9 codes used to identify sample and comorbidity based 
subgroups 
Heart Failure Asthma Diabetes Hy__]2_ertension 
428.0 493.00 250* 401* 
428.1 493.01 402.00 






U1 U1 .. 
*mcludes all 4 and 5 digit subclass1ficat10ns 
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( Table 1-3: List of generic names of medications captured within each 
t h . d 1 · d h . i · . . CHF erapeutlc cate_g_ory use to ..£.fevent morta ity an o~ta izat10n m 
Beta Blockers Angiotensin Converting Spironolactone Angiotensin II Receptor Enzyme Inhibitor Blockers (ARB) 
(ACEI) 
Atenolol Benazepril Spironolactone Candesartan 
Bisoprolol Captopril Irbesartan 
Carvedilol Enalapril Losartan 






( Table 1-4 Weighted frequency and percent occurrence of demographic 
ch t t f CHF . 't . NAMCS fi 1993 2000 arac ens 1cs o VlSl S 1Il or _years -
Characteristic Weighted* Percent of 
Frequency weighted* visits 
n = 47,188,507 within subgrou..£_s 
Period 
1993-94 12,329,611 26.1 
1995-96 12,212,841 25.9 
1997-98 11,296,468 23.9 
1999-2000 11,349,587 24.1 
Sex 
Female 24,491,634 51.9 
Male 22,696,873 48.1 
A_g_e 
0-59 5,397,099 11.5 
60-69 8,481,791 18.0 
70-79 15,665,945 33.2 
80+ 17,643,672 37.3 
Race 
White 41,179,969 87.3 
Black 4,957,055 10.5 
Other 1,051,483 2.2 
Dia_g_nosed diabetes visit 
Non-diabetic 40,599,823 86.0 
Diabetic 6,588,684 14.0 
Di~nosed asthma visit 
Non-asthmatic 46,587,112 98.7 
Asthmatic 601,395 1.3 
Dia_g_nosed b_.Il!_ertension visit 
N on-hl'.:Q_ertensi ve 38,694,590 82.0 
Hypertensive 8,493,917 18.0 
Visit _p_a_r.ment 
Private insurance 6,998,833 14.8 
Medicare 26,081,485 55.3 
Medicaid 1,786,835 3.8 
Other 590,897 1.2 
Blank or unknown 10,725,545 22.8 
HMO status 
HMO _EJ.an 6,877,066 14.6 
Non-HMO 2_lan 38,379,787 81.3 
Blank or unknown 1,931,654 4.1 
*Weighted values represent the sample adjusted to represent national visit 
characteristics 
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( Table 1-5 Weighted frequency of CHF visits and aggregate 
multiyear relative standard error (RSE) of visits 1993-2000 by year 
Visit period Number of CHF Multi-year relative 95% confidence intervals for 
visits• standard error for number of CHF visits per 2 
CHF visits ~ar_p_eriod 
1993-94 12,329,611 7.04 11,461,607-13,197,615 
1995-96 12,212,841 7.92 11,245,584-13,180,098 
1997-98 11,296,468 10.12 10, 153,266-12,439,670 
1999-2000 11,349,587 10.05 10,208,954-12,490,220 




Table 1-6 Weighted frequency and percent of medication mention rates in 
CHF from 1993-2000 by year 
Number of visits with one Relative Standard Error for Percent of visits with one 
or more dr~ mention number of mentions dru_g_ mention 
Beta Blockers 
1993-94 487,601 * 54.89 4.0t 
1995-96 581,175* 48.37 4.8t 
I 997-98 1,052,052* 58.11 9.3t 
1999-2000 1,617,562* 40.21 14.3t 
ACEI 
1993-94 3,398,254 18.89 27.6t 
1995-96 3,870,147 19.96 31.7_1_ 
1997-98 3,341,295* 30.13* 29.6_1_ 
1999-2000 4,286,231 26.68 37.8t 
~ronolactone 
1993-94 126,965* 136.74 1.0t 
1995-96 97,899* 135.99 0.8t 
1997-98 158,048* 160.45 l .4t 
1999-2000 414,960* 68.56 3.7_1_ 
ARBs 
1993-94 173,020* 88.55 1.41_ 
1995-96 137,381* 102.95 1.1_1_ 
1997-98 498,259* 82.94 4.4t 
1999-2000 530,420* 63.76 4.7t 
*Value does not meet standard of reliability or precision based upon a RSE > 30 
tValue does not meet standard of reliability or precision based upon a denominator RSE 2'.5 or a 




Table 2-1 Summary of major trials using beta blockers in CHF which measured 
mortality, hospitalizations, or a combined mortality-hospitalization effect, and 
influential guidelines 1993-2000 
Study/guideline title Journal reference Period Findings 
Cardiac Insufficiency Bisoprolol Study Circulation. 1994 1 Mortality .J.-Oct;90(4): 1765-73 Hospitalization .J.-
ACC/AHA Guidelines for the Evaluation Circulation 1995 Nov 
and Management of Chronic Heart 1 ;92(9):2764-84 2 NA Failure in the Adult 
The US Carvedilol Heart Failure Trials N Engl J Med 1996 May Mortality .J.-
Program 23 ;334(21):1349-55 2 Hospitalization .J.-
Prospective Randomized Evaluation of Circulation 1996 Dec 2 Mortality .J.-Carvedilol on Symptoms and Exercise* 1 ;94(11 ) :2793-9 
Multicenter Oral Carvedilol Heart Failure Circulation 1996 Dec Mortality .J.-
Assessment Study* 1 ;94(11 ) :2807-16 2 Hospitalizations .J.-
Heart Failure guidelines of the European Eur Heart J 1997 3 NA Society of Cardiology May; 18(5):736-53 
Study of the Safety and Efficacy of J Card Fail 1997 3 Insufficient power Carvedilol in Severe Heart Failure* Sep;3(3) : 173-9 to evaluate 
Cardiac Insufficiency Bisoprolol Study II Lancet 1999 Jan 4 Mortality .J.-2;353(9146):9-13 
Metoprolol CR/XL Randomized Lancet 1999 Jun 4 Mortality .J.-Intervention Trial in Heart Failure l 2;353(9169):2001-7 Hospitalizations .J.-
HFSA Guidelines for the Management of 
Patients with Heart Failure Caused by The Journal of Cardiac 4 NA Left Ventricular Systolic Dysfunction - Failure, 1999;5 :357-382 
Pharmacological Approaches. 
Retrospective Analysis of Studies of Left J Am Coll Cardiol. 4 Mortality .J.-Ventricular Dysfunction Treatment Trial 1999; 33 :916-923 
Beta-Blocker Survival Trial Paper presented at: 1999 
Scientific Sessions of 4 Mortality 1' the AHA; Nov. 7-10, 
1999; Atlanta, GA 
*indicates component study of US Carvedilol HF Trials Program 
NA = Not a licable 
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Table 2-2 Weighted rates of one or more drug mentions in CHF for beta blocker 
stratified by subgroup visit demographics 
N b f .. b d d f h . h b bl k um er o vts1ts ~atlent ~e an _2'._ear, an _E:rcent o t e~ven n wit a eta oc ers mention. 
0-59 60-69 70-79 80+ 
Year n % n % N % N % 
1993-94 1229933 10.9 2069616 2.4% 4016916 4.1% 5013146 2.8% 
1995-96 1223361 4.1% 2024943 2.9% 4633977 4.4% 4330560 6.2% 
1997-98 1255262 8.7% 2055364 7.5% 3867993 6.8% 4117849 12.7% 
1999-2000 1688543 16.6% 2331868 21.4% 3147059 12.4% 4182117 10.7% 
N b f . . b um er o vts1ts ~sex an d d f h . h b bl k ~ar, an _E_ercent o t e~ven n wit a eta oc er mention 
Female Male 
Year n % n % 
1993-94 7124629 3.2 5204982 5.0 
1995-96 6282195 2.4 5930646 7.2 
1997-98 5562697 5.6 5733771 12.9 
1999-2000 5522113 11.3 5827474 17.0 
N b f .. b d d f h . h b bl k um er o v1s1ts ~race an ~ar, an _E_ercent o t e~ven n wit a eta oc er ment10n 
White Non-white 
Year n % n % 
1993-94 10733051 3.4 1596560 7.7 
1995-96 10776537 5.3 1436304 .6 
1997-98 9926163 8.9 1370305 12.3 
1999-2000 9744218 15.9 1605369 4.2 
Number of visits by recorded diabetic diagnosis and year, and percent of the given n with a beta blocker 
mention 
Non-diabetic Diabetic 
Year n % n % 
1993-94 10772854 4.5 1556757 0 
1995-96 10535885 5.4 1676956 0.5 
1997-98 9727608 9.0 1568860 11.3 
1999-2000 9563476 15.3 1786111 8.8 
Number of visits by recorded hypertensive diagnosis and year, and percent of the given n with a beta blocker 
mention 
Non-h_i'Il_ertensive Hypertensive 
Year n % n % 
1993-94 10301868 3.7 2027743 5.0 
1995-96 10349848 5.2 1862993 2.4 
1997-98 8888661 9.1 2407807 10.2 
1999-2000 9154213 13.4 2195374 17.8 
N b f . . b HMO um er o v1s1ts ~ d d f h "th b bl status an _2'._ear, an _E_ercent o t e _g_iven n w1 a eta ocker men ti on 
HMOjl_lan Non-HMO _E}an 
Year n % n % 
1993-94 1401535 6.1 10928076 3.7 
1995-96 1916046 7.3 10296795 4.3 
1997-98 1645452 17.0 9176491 7.4 
1999-2000 1914033 24.3 7978425 11.4 
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( Table 2-3 Logistic regression model for identifying significant predictors of beta 
blocker drug mentions in CHF visits 
Predictor Variables Odds Ratio 95% Confidence Interval 
Period 1, 1993-94 (referent) 
Period 2, 1995-96 1.171 1.166- 1.176 
Period 3, 1997-98 2.333 2.325 - 2.341 
Period 4, 1999-2000 3.754 3.741 - 3.766 
Age 0-59 (referent) 
Age 60-69 .763 .761 - .766 
Age 70-79 .580 .578 - .582 
Age 80+ .728 .725 - .730 
Sex female (referent) 
Sex male 1.945 1.940 - 1.949 
Race White (referent) 
Race Non-white .690 .687 - .692 
Non-diabetic (referent) 
Diabetic .585 .583 - .587 
Non-hypertensive (referent) 
Hypertensive 1.177 1.173 - 1.180 
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Table 3-1 Summary of major trials using ACE inhibitors in CHF which measured 
mortality, hospitalizations, or a combined mortality-hospitalization effect, and 
influential guidelines 1987-2000 
Study/guideline title Journal reference Period Findings 
Effects of enalapril on mortality in 
severe congestive heart failure. Results 
of the Cooperative North Scandinavian N Engl J Med 1987 Jun NA Mortality"" Enalapril Survival Study 4;316(23): 1429-35 
(CONSENSUS). The CONSENSUS 
Trial Study Group. 
Effect of enalapril on survival in patients 
Mortality"" with reduced left ventricular ejection N Engl J Med 1991 Aug NA fractions and congestive heart failure. I ;325(5):293-302 Hospitalization "" 
The SOLVD Investigators. 
A comparison of enalapril with 
hydralazine-isosorbide dinitrate in the N Engl J Med 1991 Aug NA Mortality"" treatment of chronic congestive heart I ;325(5):303-10 
failure. 
Effect of captopril on mortality and 
morbidity in patients with left ventricular 
dysfunction after myocardial infarction. N Engl J Med 1992 Sep NA Mortality"" Results of the survival and ventricular 3;327(10):669-77 
enlargement trial. The SAVE 
Investigators. 
Effect of enalapril on mortality and the 
development of heart failure in N Engl J Med 1992 Sep Mortality"" 
asymptomatic patients with reduced left 3;327(10):685-91 NA Hospitalization "" ventricular ejection fractions. The 
SOL VD Investigators. 
ACC/AHA Guidelines for the Evaluation Circulation 1995 Nov 
and Management of Chronic Heart I ;92(9):2764-84 2 NA Failure in the Adult 
Heart Failure guidelines of the Eur Heart J 1997 3 NA European Society of Cardiology May; 18(5):736-53 
HFSA Guidelines for the Management 
of Patients with Heart Failure Caused The Journal of Cardiac 4 NA by Left Ventricular Systolic Dysfunction Failure, I 999;5:357-382 
- Pharmacological Approaches. 
NA = Not a licable 
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Table 3-2 Weighted rates of one or more drug mentions in CHF for ACEis 
stratified by subgroup visit demographics 
N b f .. b d d f h . h ACE! um er o v1s1ts ~t1ent ~an ~ar, an _E_ercent o t e_.&!ven n wit an mention. 
0-59 60-69 70-79 80+ 
Year n % n % N % N 
1993-94 1229933 41.7 2069616 30.1 4016916 26.1 5013146 
1995-96 1223361 35.9 2024943 23.9 4633977 29.7 4330560 
1997-98 1255262 28.4 2055364 29.4 3867993 35.2 4117849 
1999-2000 1688543 38.0 2331868 44.5 3147059 27.8 4182117 
N b f .. b d d f h . h ACEI um er o v1s1ts ~sex an y_ear, an _E_ercent o t e _&!Ven n wit an mention 
Female Male 
Year n % N % 
1993-94 7124629 26.2 5204982 29.4 
1995-96 6282195 32.5 5930646 30.9 
1997-98 5562697 30.7 5733771 28 .5 
1999-2000 5522113 38.8 5827474 36.8 
N b f .. b d d f h . h ACEI um er o v1s1ts ~race an y_ear, an _E_ercent o t e _&!Ven n wit an mention 
Whjte Non-white 
Year n % n % 
1993-94 10733051 27 .0 1596560 31.6 
1995-96 10776537 32.2 1436304 27.9 
1997-98 9926163 29.l 1370305 33.2 






N b f .. b d d d' b . d' d d f h h ACEI mention um er o v1s1ts ~ recor e ia et1c 1~nos1s an ~ar, an 2_ercent o t e_.&!ven n wit an 
Non-diabetic Diabetic 
Year n % n % 
1993-94 10772854 26.7 1556757 33 .2 
1995-96 10535885 32.6 1676956 25 .7 
1997-98 9727608 27.6 1568860 42.1 
1999-2000 9563476 33.7 1786111 59.8 
Number of visits by recorded hypertensive diagnosis and year, and percent of the given n with an ACE! 
mention 
Non-h_l'2_ertensive H J:'2_ertensive 
Year n % n % 
1993-94 10301868 27.7 2027743 27.0 
1995-96 10349848 31.5 1862993 33.0 
1997-98 8888661 28.1 2407807 35 .1 
1999-2000 9154213 37.9 2195374 37.2 
N b f . . b HMO um er o v1s1ts 'J'j_ d d f h . h ACEI status an y_ear, an _E_ercent o t e_s!ven n wit an mention 
HM0_£1an Non-HMO _E_lan 
Year n % n % 
1993-94 1401535 34.9 10928076 26.6 
1995-96 1916046 32.9 10296795 31.5 
1997-98 1645452 34.l 9176491 27.8 
1999-2000 1914033 36.9 7978425 36.6 
34 
( Table 3-3 Logistic regression model for identifying significant predictors of ACEI 
drug mentions in CHF visits 
Predictor Variables Odds Ratio 95% Confidence Interval 
Period 1, 1993-94 (referent) 
Period 2, 1995-96 1.221 1.219-1.223 
Period 3, 1997-98 1.094 1.092-1.096 
Period 4, 1999-2000 1.557 1.554-1.559 
Age 0-59 (referent) 
Age 60-69 .852 .850-.854 
Age 70-79 .812 .811-.814 
Age 80+ .868 .866-.870 
Sex female (referent) 
Sex male 1.010 1.009-1.012 
Race White (referent) 
Race Non-white 1.051 1.049-1.053 
Non-diabetic (referent) 
Diabetic 1.558 1.555-1.561 
Non-hypertensive (referent) 
Hypertensive 1.087 1.086-1.089 
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Table 4-1 Summary of major trials using spironolactone in CHF which measured 
mortality, hospitalizations, or a combined mortality-hospitalization effect, and 
influential guidelines 1993-2000 
Study/guideline title Journal reference Period Findings 
ACC/AHA Guidelines for the Evaluation Circulation 1995 Nov 
and Management of Chronic Heart I ;92(9):2764-84 2 NA Failure in the Adult 
Heart Failure guidelines of the Eur Heart J 1997 3 NA European Society of Cardiology May; 18(5):736-53 
HFSA Guidelines for the Management 
of Patients with Heart Failure Caused The Journal of Cardiac 4 NA by Left Ventricular Systolic Dysfunction Failure, l 999;5:357-382 
- Pharmacological Approaches. 
The effect of spironolactone on 
morbidity and mortality in patients with N Engl J Med 1999 Sep Mortality .J.. 
severe heart failure . Randomized 2;341(I0):709-17 4 Hospitalizations .J.. Aldactone Evaluation Study 
Investigators. 
NA =Not a licable 
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( Table 4-2 Weighted rates of one or more drug mentions in CHF for spironolactone stratified by subgroup visit demographics 
N b f .. b d d fh ' h um er o v1s1ts ~at1ent ~e an _}'._ear, an _JJ_ercent o t e_given n wit a ~rono actone mention. 
0-59 60-69 70-79 80+ 
Year n % n % N % N % 
1993-94 1229933 0.1 2069616 2.3 4016916 0 5013146 1.5 
1995-96 1223361 1.2 2024943 0.3 4633977 1.0 4330560 0.7 
1997-98 1255262 0.5 2055364 2.3 3867993 2.7 4117849 0 
1999-2000 1688543 9.0 2331868 1.0 3147059 2.8 4182117 3.6 
N b f .. b um er o v1s1ts ~sex an d d fh ' h ~ar, an _E_ercent o t e _given n wit a ~rono actone mention 
Female Male 
Year n % n % 
1993-94 7124629 1.3 5204982 0.7 
1995-96 6282195 1.2 5930646 0.4 
1997-98 5562697 0.7 5733771 2.1 
1999-2000 5522113 4.0 5827474 3.3 
N b f .. b d d fh 'h um er o v1s1ts ~race an _year, an _E_ercent o t e_given n wit a ~rono actone mention 
White Non-white 
Year n % n % 
1993-94 10733051 1.2 1596560 0.1 
1995-96 10776537 0.6 1436304 2.6 
1997-98 9926163 1.6 1370305 0 
1999-2000 9744218 3.2 1605369 6.4 
Number of visits by recorded diabetic diagnosis and year, and percent of the given n with a spironolactone 
mention 
Non-diabetic Diabetic 
Year n % n % 
1993-94 10772854 1.2 1556757 0 
1995-96 10535885 0.9 1676956 0 
1997-98 9727608 1.6 1568860 0 
1999-2000 9563476 3.3 1786111 5.5 
Number of visits by recorded hypertensive diagnosis and year, and percent of the given n w ith a 
s . I . E!rono actone mention 
Non-~ertensive H_.YE._ertensive 
Year n % n % 
1993-94 10301868 0.8 2027743 2.4 
1995-96 10349848 0.9 1862993 0.5 
1997-98 8888661 0.7 2407807 3.9 
1999-2000 9154213 3.8 2195374 3.2 
N b f .. b HMO t t d d t f th um er o v1s1ts ~ s a us an _}'._ear, an _E_ercen o 'th e_given n w1 a ~rono actone m en ti on 
HMO_Q(an Non-HMO~an 
Year n % n % 
1993-94 1401535 0 10928076 1.2 
1995-96 1916046 0 10296795 1.0 
1997-98 1645452 0 9176491 1.7 
1999-2000 1914033 0 7978425 3.6 
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( Table 4-3 Logistic regression model for identifying significant predictors of 
spironolactone drug mentions in CHF visits 
Predictor Variables Odds Ratio 95% Confidence Interval 
Period 1, 1993-94 (referent) 
Period 2, 1995-96 .792 .786-.799 
Period 3, 1997-98 1.347 1.337-1.357 
Period 4, 1999-2000 3.542 3.519-3 .564 
Age 0-59 (referent) 
Age 60-69 .510 .506-.513 
Age 70-79 .589 .586-.593 
Age 80+ .537 .533-.540 
Sex female (referent) 
Sex male .884 .880-.888 
Race White (referent) 
Race Non-white 1.158 1.151-1.165 
Non-diabetic (referent) 
Diabetic .780 .775-.786 
Non-hypertensive (referent) 
Hypertensive 1.551 1.543-1.559 
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( Table 5-1 Summary of major trials using ARBs in CHF which measured 
mortality, hospitalizations, or a combined mortality-hospitalization effect, and 
influential guidelines 1993-2000 
Study/guideline title Journal reference Period Findings 
ACC/AHA Guidelines for the Evaluation Circulation 1995 Nov 
and Management of Chronic Heart I ;92(9):2764-84 2 NA Failure in the Adult 
Randomized trial of losartan versus CHF mortality no 
captopril in patients over 65 with heart Lancet 1997 Mar different from failure (Evaluation of Losartan in the I 5;349(9054):747-52 3 ACEI, but all Elderly Study, ELITE) 
cause mortality "-' 
Heart Failure guidelines of the Eur Heart J 1997 3 NA European Society of Cardiology May; 18(5):736-53 
HFSA Guidelines for the Management 
of Patients with Heart Failure Caused by The Journal of Cardiac 4 NA Left Ventricular Systolic Dysfunction - Failure, 1999;5:357-382 
Pharmacological Approaches. 
Effect of losartan compared with 
Mortality no captopril on mortality in patients with Lancet 2000 May 
symptomatic heart failure: randomized 4 different from 
trial--the Losartan Heart Failure Survival 6;355(9215): 1582-7 ACEI Study ELITE II. 
NA =Not applicable 
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( Table 5-2 Weighted rates of one or more drug mentions in CHF for ARBs stratified by subgroup visit demographics 
N b f .. b d d fh "h um er o v1s1ts ~t1ent ~an ~ar, an __.E_ercent o t e~ven n wit an ARB mention. 
0-59 60-69 70-79 80+ 
Year n % n % N % N 
1993-94 1229933 2.8 2069616 0 4016916 3.0 5013146 
1995-96 1223361 1.8 2024943 2.4 4633977 0.8 4330560 
1997-98 1255262 2.0 2055364 3.6 3867993 7.2 4117849 
1999-2000 1688543 2.7 2331868 1.8 3147059 7.9 4182117 
N b f .. b d d fh "h um er o v1s1ts ~sex an 1ear, an _.12._ercent o t e _&!Ven n wit an ARB mention 
Female Male 
Year n % n % 
1993-94 7124629 1.8 5204982 0.9 
1995-96 6282195 1.2 5930646 1.0 
1997-98 5562697 5.0 5733771 3.8 
1999-2000 5522113 5.4 5827474 4.0 
N b f .. b d d f h . . h ARB um er o v1s1ts ~race an _}'ear, an _.12._ercent o t e _&!Ven n wit an mention 
White Non-white 
Year n % n % 
1993-94 10733051 1.0 1596560 4.4 
1995-96 10776537 1.1 1436304 1.3 
1997-98 9926163 3.8 1370305 8.9 






N b f .. b d d d" b . d" d d f h · h ARB mention um er o v1s1ts ~recor e 1a et1c 1~os1s an 1ear, an 2_ercent o t e_.s!ven n wit an 
Non-diabetic Diabetic 
Year n % n % 
1993-94 10772854 1.5 1556757 1.1 
1995-96 10535885 1.3 1676956 0 
1997-98 9727608 5.0 1568860 0.7 
1999-2000 9563476 5.0 1786111 2.7 
Number of visits by recorded hypertensive diagnosis and year, and percent of the given n with an ARB 
mention 
Non-~ertensive H _i'.E_ertensive 
Year n % n % 
1993-94 10301868 0.3 2027743 7.2 
1995-96 10349848 0.9 1862993 2.5 
1997-98 8888661 3.9 2407807 6.3 
1999-2000 9154213 4.1 2195374 7.1 
N b f .. b HMO um er o v1s1ts ~ d d f h .h ARB status an 1ear, an _.12._ercent o t e _&!Ven n wit an mention 
HMO_E_lan Non-HMO _E!an 
Year n % n % 
1993-94 1401535 0 10928076 1.6 
1995-96 1916046 1.2 10296795 1.1 
1997-98 1645452 3.7 9176491 4.7 
1999-2000 1914033 3.0 7978425 5.3 
40 
Table 5-3 Logistic regression model for identifying significant predictors of ARB 
drug mentions in CHF visits 
Predictor Variables Odds Ratio 95% Confidence Interval 
Period 1, 1993-94 (referent) 
Period 2, 1995-96 .794 .788-.799 
Period 3, 1997-98 3.115 3.097-3 .132 
Period 4, 1999-2000 3.767 3.746-3.788 
Age 0-59 (referent) 
Age 60-69 .991 .984-.999 
Age 70-79 2.275 2.260-2.289 
Age 80+ 1.058 1.050-1.065 
Sex female (referent) 
Sex male .673 .670-.675 
Race White (referent) 
Race Non-white 1.259 1.253-1.264 
Non-diabetic (referent) 
Diabetic .375 .373-.378 
Non-hypertensive (referent) 
Hypertensive 2.512 2.503-2.521 
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( Appendix A: List of Definitions 
ICD-9 = The International Classification of Diseases Revision 9 is a coding system 
which enables payers and providers of health services to efficiently 
communicate diagnoses. 
NAMCS =The National Ambulatory Medical Care Survey is an annually 
performed national probability survey which records an extensive and 
varied list of characteristics regarding visits to physicians in the United 
States. The survey is designed to describe the use of ambulatory services in 
the US. 
NCHS =The National Center for Health Statistics is a branch of the Centers for 
Disease Control (CDC), which falls under the U.S. Department of Health 
and Human Services (HHS). This department provides key health 
surveillance information which is utilized by a diverse set of stakeholders to 
identify issues and direct policy. 
RSE = The Relative Standard Error is used to measure the reliability and 
precision of a sample by capturing the degree sampling variability and 
nonsystematic biases present in the sample. The RSE can be translated to a 
confidence interval by multiplying the RSE by the estimate to obtain the 
standard error. There is a 95% confidence that the true value lies within 
twice the standard error of the estimated value. 
SPSS =The Statistical Package for the Social Sciences is a analytical software 
product with a broad statistical capabilities to aid in decision making. It 
42 
( utilizes a graphical user interface, which often facilitates intuitive data 
manipulation and analysis. 
SUDAAN = A statistical software package, formerly named Survey Data Analysis, 
which specializes in the analysis of cluster-correlated data. SUDAAN takes 
into account the complex sampling design of the NAMCS, eliminating the 
need of less powerful approximation equations. 
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Appendix B: Excerpt from NCHS internal memo on RSE estimation for aggregate 
measures using multi year NAM CS data 
by I.M. Shimizu, 
December 9, 1993 
Sampling Errors for Estimates Based on Multi-Years ofNAMCS Data 
This document presents procedures which one may use to approximate sampling 
errors of estimates based on NAM CS data collected across multiple years. 
1. Variance of estimated aggregate across years 
For discussion purposes, let: 
Yi = estimated total based on data from the individual year i. 
k 
Y=L:t be the estimated aggregate NAMCS total across k years ofNAMCS 
data. 
i - 1 
F be that year in which NAM CS had the fewest number of responding 
physicians among the years included in the study (1 :SF :S k) . (Table 1 gives 
numbers ofrespondents for 1989-92.) 
Var (Yr)= Variance ofYrderived from the appropriate NAMCS error curve for 
year F. 
Then the variance of Y may be approximated with 
V~(Y) =Var (Yr)[k(2/I- 1) - 2/1+2], 
where 
I= 0.9 for statistic for all physicians (without regard to specialty), for 
pediatricians only, or for OB/GYNs only. 
1 for statistics for internal medicine specialty only. 
0.8 for all other physician groups. 
The approximation formulated in this equation is believed to be conservative. That 
is, the approximation should overstate, rather than understate, the variance 
for most multi-year aggregate estimates based on NAMCS data. 
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Appendix C: Excerpt from NCHS internal memo on RSE estimation for 
proportions using multiyear NAM CS data 
by David A. Woodwell, 
November 4, 2002 
Question: Is there a recommended procedure for estimating the variance of a 
proportion when combining several years of NAM CS data? 
Response: 
FIRST SOME NOTATION: 
Let x(i) and y(i) be binomial characteristics of interest for the ith sample unit. 
x(i) = 1 or 0 and y(i) = 0 or 1. 
Let X =sum ofx(i) over the sample units. Let Y =sum of y(i) over the sample 
units. 
LetR=X/Y. 
If x(i) = 1 only when y(i) = 1, then R = X!Y is a proportion [the x(i)=l units are a 
subset of the y(i)=l units] 
THEN 
When both X and Y are estimated from the same survey, then a crude 
approximation typically used by NCHS analysts for the RSE of the proportion is: 
RSE(R) = RSE(XIY) =square root of [square RSE(X) - square RSE(Y)] 
provided RSE(Y) < 0.05 or both RSE(X) <0.10 AND RSE(Y) < 0.10. If the 
conditions fail, your estimate is not stable. The RSE(X) and RSE(Y) are 
approximated in the same way as any other multi-year aggregate statistic. The A 
and B parameters of error curves for X and Y should be taken from the same year 
to prevent negative results. 
If the X and Y are estimated from different surveys, then 
RSE(R) = RSE(XIY) =square root of [square RSE(X) +square RSE(Y)], 
again provided the conditions are satisfied. 
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